| Previous Close | 0.1900 |
| Open | 0.1850 |
| Bid | 0.1850 x 0 |
| Ask | 0.1950 x 0 |
| Day's Range | 0.1850 - 0.1850 |
| 52 Week Range | 0.0350 - 0.3500 |
| Volume | 3,000 |
| Avg. Volume | 311,958 |
| Market Cap | 28.206M |
| Beta (5Y Monthly) | 2.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0130 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Neutrisci Announces New State-Of-The-Art Production and Research Facility in Las Vegas, Nevada, USA
VANCOUVER, BC / ACCESSWIRE / March 18, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V:NU)(OTCQB:NRXCF)(FRANKFURT:1N9), an innovative technology company developing products for the nutraceutical industry, is very pleased to announce the completion of its newly dedicated production line and research lab in Las Vegas, Nevada.
- ACCESSWIRE
NeutriSci: Harmonized Code Approval Received by TABLETZ LLC., in Japan
VANCOUVER, BC / ACCESSWIRE / March 8, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV:NU)(OTCQB:NRXCF)(FRA:1N9), an innovative technology company developing products for the nutraceutical industry, in conjunction with its partner, Tabletz LLC, is very pleased to announce that its partner Tabletz LLC.
- ACCESSWIRE
NeutriSci Closes Financing
VANCOUVER, BC / ACCESSWIRE / January 29, 2021/ NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV:NU)(OTCQB:NRXCF)(FRANKFURT:1N9), an innovative technology company developing products for the nutraceutical industry, is pleased to announce that it has closed a non-brokered private placement (the "Placement") in which it raised gross proceeds of $370,050.
